<DOC>
	<DOCNO>NCT00002583</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy effective treatment non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness vinorelbine plus cisplatin therapy treat patient stage I stage II non-small cell lung cancer completely remove surgery .</brief_summary>
	<brief_title>Vinorelbine Plus Cisplatin No Further Therapy Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : I . Compare duration overall disease-free survival patient completely resect non-small cell lung cancer ( NSCLC ) randomize adjuvant chemotherapy vinorelbine cisplatin versus observation . II . Confirm prognostic significance ra mutation present primary tumor . III . Provide comprehensive tumor bank link clinical database study molecular marker resect NSCLC . IV . Measure compare health-related quality life patient treatment arm . V. Evaluate toxicity relate treatment regimen . OUTLINE : This randomize study . Patients stratify accord participate institution , nodal status ( N0 v N1 ) , ras mutation status primary tumor ( absent v present vs unknown ) . Patients randomize one two treatment arm . Arm I : Patients evaluate 3 6 month randomization . Arm II : Patients receive vinorelbine IV 6-10 minute weekly 16 week . Patients also receive cisplatin IV day 1 8 every 4 week total 4 course . Treatment continue absence disease progression unacceptable toxicity . Quality life assess Canadian center . Quality life assessment optional ECOG SWOG center . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 450 patient accrue study within 6.75 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary nonsmall cell lung cancer completely resect No mixed small nonsmall cell histology Pathologic T2 N0 T12 N1 T1 N1 T2 N1 CALGB institution Removal gross disease negative resection margin lobectomy , sleeve resection , bilobectomy , pneumonectomy ( base intraoperative finding ) No segmentectomy wedge resection Complete mediastinal lymph node resection sampling require primary tumor resection , minimum level nodal sample follow : Primary right upper lobe level 4 , 7 , 10 Primary right middle lobe level 4 , 7 , 10 Primary right low lobe level 4 , 7 , 9 , 10 Primary leave upper lobe level 5 , 6 , 7 , 10 Primary leave low lobe level 7 , 9 , 10 If complete mediastinal lymph node resection undertaken , mediastinal lymph node measure 1.5 cm presurgical CT scan must biopsied find free metastatic involvement Disease nodal station 10 ( tracheobronchial angle ) consider N2 disease trial eligible No one discrete primary tumor No bronchoalveolar carcinoma lobar multilobar involvement Discrete solitary radiological mass nodule eligible Snap frozen fresh primary tumor tissue must submit Lung Cancer Tumor Bank within 14 day surgery select Canadian center Others submit representative paraffin block within 2 month surgery PATIENT CHARACTERISTICS : Age : 18 ( low age limit determine individual center ) Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count great 2,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 10.0 g/dL Hepatic : Bilirubin great 1.25 time normal AST/ALT great 1.25 time normal Alkaline phosphatase great 1.25 time normal Renal : Creatinine great 1.7 mg/dL Cardiovascular : No history congestive heart failure cardiac abnormality may preclude hydration necessary cisplatin administration Other : No active pathologic condition would preclude study No active uncontrolled infection No history psychiatric neurologic disorder would preclude study No prior breast cancer , melanoma , hypernephroma No malignancy within past 5 year except adequately treat nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception Ability tolerate treatment ( base consultation thoracic surgeon medical oncologist hematologist ) available followup PRIOR CONCURRENT THERAPY : Complete resection require Randomization 28 40 day surgery require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
</DOC>